Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH002-mediated Sonoporation With Nanoliposomal Irinotecan, Leucovorin, and 5-Fluorouracil in Pancreatic Cancer With Liver Metastasis
NCT07314385Phase 1Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of perflutren lipid microspheres in pancreatic ductal adenocarcinoma (PDAC) and liver metastasis (4 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)liver metastasis
Beyond the preview
Go deeper on NCT07314385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314385.